公开(公告)号：US11498913B2

公开(公告)日：2022-11-15

申请号：US17101018

申请日：2020-11-23

Applicant: FORMA Therapeutics, Inc.

Inventor： Jian Lin ,  Anna Ericsson ,  Ann-Marie Campbell ,  Gary Gustafson ,  Zhongguo Wang ,  R. Bruce Diebold ,  Susan Ashwell ,  David R. Lancia, Jr. ,  Justin Andrew Caravella ,  Wei Lu

IPC: C07D401/12 ,  C07D401/14 ,  C07D471/04 ,  A61P35/00 ,  A61K31/47

Abstract: The invention relates to inhibitors of mutant isocitrate dehydrogenase (mt-IDH) proteins with neomorphic activity useful in the treatment of cell-proliferation disorders and cancers, having the Formula: where A, U, W1, W2, W3, R1-R6, and R9 are described herein.

公开(公告)号：US11299484B2

公开(公告)日：2022-04-12

申请号：US17021759

申请日：2020-09-15

Applicant: FORMA Therapeutics, Inc.

Inventor： Matthew W. Martin ,  Mary-Margaret Zablocki ,  Scot Mente ,  Christopher Dinsmore ,  Zhongguo Wang ,  Xiaozhang Zheng

IPC: C07D405/14 ,  C07D221/20 ,  C07D409/14 ,  C07D413/14 ,  C07D405/06

Abstract: The present disclosure is directed to inhibitors of FASN. The compounds can be useful in the treatment of disease or disorders associated with the inhibition of FASN. For instance, the disclosure is concerned with compounds and compositions for inhibition of FASN, methods of treating, preventing, or ameliorating diseases or disorders associated with the inhibition of FASN, and methods of synthesis of these compounds.

公开(公告)号：US10913753B2

公开(公告)日：2021-02-09

申请号：US16077407

申请日：2017-02-13

Applicant: FORMA Therapeutics, Inc.

Inventor： David Joseph Guerin ,  Kenneth W. Bair ,  Justin A. Caravella ,  Stephanos Ioannidis, Jr. ,  David R. Lancia, Jr. ,  Hongbin Li ,  Steven Mischke ,  Pui Yee Ng ,  David Richard ,  Shawn E. R. Schiller ,  Tatiana Shelekhin ,  Zhongguo Wang

IPC: C07D519/00 ,  C07D495/04

Abstract: The disclosure relates to inhibitors of USP28 and/or USP25 useful in the treatment of cancers, inflammation, autoimmune diseases, and infectious diseases, having the Formula: where R1, R2, R3, R4, R5, R5′, R6, R7, X, m, and n are described herein.

公开(公告)号：US20210024508A1

公开(公告)日：2021-01-28

申请号：US17021759

申请日：2020-09-15

Applicant: FORMA Therapeutics, Inc.

Inventor： Matthew W. Martin ,  Mary-Margaret Zablocki ,  Scot Mente ,  Christopher Dinsmore ,  Zhongguo Wang ,  Xiaozhang Zheng

IPC: C07D405/14 ,  C07D221/20 ,  C07D409/14 ,  C07D413/14 ,  C07D405/06

Abstract: The present disclosure is directed to inhibitors of FASN. The compounds can be useful in the treatment of disease or disorders associated with the inhibition of FASN. For instance, the disclosure is concerned with compounds and compositions for inhibition of FASN, methods of treating, preventing, or ameliorating diseases or disorders associated with the inhibition of FASN, and methods of synthesis of these compounds.

公开(公告)号：US10889567B2

公开(公告)日：2021-01-12

申请号：US16712951

申请日：2019-12-12

Applicant: FORMA Therapeutics, Inc.

Inventor： Jian Lin ,  Anna Ericsson ,  Ann-Marie Campbell ,  Gary Gustafson ,  Zhongguo Wang ,  R. Bruce Diebold ,  Susan Ashwell ,  David R. Lancia, Jr. ,  Justin Andrew Caravella ,  Wei Lu

IPC: C07D401/12 ,  C07D401/14 ,  C07D471/04 ,  A61P35/00 ,  A61K31/47

Abstract: The invention relates to inhibitors of mutant isocitrate dehydrogenase (mt-IDH) proteins with neomorphic activity useful in the treatment of cell-proliferation disorders and cancers, having the Formula: where A, U, W1, W2, W3, R1-R6, and R9 are described herein.

公开(公告)号：US20200253939A1

公开(公告)日：2020-08-13

申请号：US15929436

申请日：2020-05-01

Applicant: FORMA Therapeutics, Inc.

Inventor： Anna Ericsson ,  Neal Green ,  Gary Gustafson ,  David R. Lancia ,  Gary Marshall ,  Lorna Mitchell ,  David Richard ,  Zhongguo Wang

IPC: A61K31/436 ,  A61K9/00 ,  A61P7/06

Abstract: This disclosure provides compounds and compositions for activating pyruvate kinase R (PKR) and related methods of manufacturing and using these compounds and compositions.

公开(公告)号：US20180134682A1

公开(公告)日：2018-05-17

申请号：US15712446

申请日：2017-09-22

Applicant: FORMA Therapeutics, Inc.

Inventor： Jian Lin ,  Anna Ericsson ,  Ann-Marie Campbell ,  Gary Gustafson ,  Zhongguo Wang ,  R. Bruce Diebold ,  Susan Ashwell ,  David R. Lancia, Jr. ,  Justin Andrew Caravella ,  Wei Lu

IPC: C07D401/12 ,  C07D405/14 ,  C07D401/14 ,  C07D403/12 ,  C07D471/04 ,  C07D409/14 ,  C07D413/14 ,  C07D417/14

CPC classification number: C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D405/14 ,  C07D409/14 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04

Abstract: The invention relates to inhibitors of mutant isocitrate dehydrogenase (mt-IDH) proteins with neomorphic activity useful in the treatment of cell-proliferation disorders and cancers, having the Formula: where A, B, W1, W2, W3, and R1-R6 are described herein.

公开(公告)号：US20180086733A1

公开(公告)日：2018-03-29

申请号：US15677748

申请日：2017-08-15

Applicant: FORMA Therapeutics, Inc.

Inventor： Jian Lin ,  Anna Ericsson ,  Ann-Marie Campbell ,  Gary Gustafson ,  Zhongguo Wang ,  R. Bruce Diebold ,  Susan Ashwell ,  David R. Lancia, JR. ,  Justin Andrew Caravella ,  Wei Lu

IPC: C07D401/12 ,  C07D417/14 ,  C07D413/14 ,  C07D405/14 ,  C07D401/14 ,  A61K31/4704

CPC classification number: C07D401/12 ,  A61K31/4704 ,  C07D401/14 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14

Abstract: The invention relates to inhibitors of mutant isocitrate dehydrogenase (mt-IDH) proteins with neomorphic activity useful in the treatment of cell-proliferation disorders and cancers, having the Formula: where A, B, U, V, Z, W1, W2, W3, and R1-R6 are described herein.

公开(公告)号：US20160083349A1

公开(公告)日：2016-03-24

申请号：US14858174

申请日：2015-09-18

Applicant: Forma Therapeutics, Inc.

Inventor： Jian Lin ,  Anna Ericsson ,  Ann-Marie Campbell ,  Gary Gustafson ,  Zhongguo Wang ,  R. Bruce Diebold ,  Susan Ashwell ,  David R. Lancia, JR. ,  Justin Andrew Caravella ,  Wei Lu

IPC: C07D215/227 ,  C07D401/12

CPC classification number: C07D215/227 ,  C07D401/12 ,  C07D405/12 ,  C07D409/12 ,  C07D471/04

Abstract: The invention relates to inhibitors of mutant isocitrate dehydrogenase (mt-IDH) proteins with neomorphic activity useful in the treatment of cell-proliferation disorders and cancers, having the Formula: where A, B, W1, W2, W3, and R1-R8 are described herein.

Abstract translation: 本发明涉及用于治疗细胞增殖障碍和癌症的具有新形态活性的突变异柠檬酸脱氢酶（mt-IDH）蛋白的抑制剂，其具有下式：其中A，B，W1，W2，W3和R1-R8是 在此描述。

公开(公告)号：US20240150319A1

公开(公告)日：2024-05-09

申请号：US18506060

申请日：2023-11-09

Applicant: FORMA Therapeutics, Inc.

Inventor： Jian Lin ,  Anna Ericsson ,  Ann-Marie Campbell ,  Gary Gustafson ,  Zhongguo Wang ,  R. Bruce Diebold ,  Susan Ashwell ,  David R. Lancia, JR. ,  Justin Andrew Caravella ,  Wei Lu

IPC: C07D401/12 ,  A61P35/00 ,  C07D401/14 ,  C07D471/04

CPC classification number: C07D401/12 ,  A61P35/00 ,  C07D401/14 ,  C07D471/04 ,  A61K31/47

Abstract: The invention relates to inhibitors of mutant isocitrate dehydrogenase (mt-IDH) proteins with neomorphic activity useful in the treatment of cell-proliferation disorders and cancers, having the Formula:




where A, U, W1, W2, W3, R1-R6, and R9 are described herein.